Trials / No Longer Available
No Longer AvailableNCT00852345
Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy
Clofazamine in the Long Term Treatment of Leprosy, Phase III
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Kaiser Permanente · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Clofazimine has shown effectiveness in the treatment of leprosy for many years. The World Health Organization and the National Hansen's Disease Program consider clofazamine to be standard therapy for treatment of multibacillary leprosy. In recent years, the availability of the drug has become limited and is currently available only under a research protocol and is considered "investigational." Use of Clofazamine in patients presenting with lepromatous leprosy is necessary for patients exhibiting nerve involvement or lesions resistant to other therapies. This drug will be used prospectively for patients who require treatment of leprosy as deemed appropriate by a Kaiser Permanente Southern California physician.
Detailed description
Treatment protocol objective is to treat patients with clofazamine who meet inclusion criteria stated above.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | clofazamine | clofazamine 50mg po qday (duration varies according to physician) |
Timeline
- First posted
- 2009-02-27
- Last updated
- 2015-04-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00852345. Inclusion in this directory is not an endorsement.